Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The primary purposes of this research study are to determine the safety and tolerability of dose levels of the investigational drug, XmAb20717, and if XmAb20717 works in treating advanced solid tumors that have progressed after treatment with standard cancer therapies or solid tumors for which there are no appropriate therapies …
This is a Phase 1/2, multicenter, open label, study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat …
Request for collaborative review: WIRB serving as IRB of record.
The purpose of this research study is to: • Test how safe RP-6306 and gemcitabine are when given together at different doses and on different schedules • Test how well RP-6306 and gemcitabine work together to shrink cancer in the body RP-6306 is a PKMYT1 inhibitor that is designed to …
The research study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on subjects with cancer who plan to be treated as part of the clinical care. The imaging agent could help the doctor see where your CD8+ T cells …
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.
